Perkins Coie Advises Pacira BioSciences, Inc. in $402-Million Convertible Note Offering

DENVER (July 7, 2020)—Perkins Coie represented New Jersey-based pharmaceuticals company, Pacira Biosciences, Inc., in its $402-million offering of convertible senior notes in a private placement pursuant to Rule 144A under the Securities Act of 1933.

The Firmwide Chair of Perkins Coie's Corporate Practice, Jason Day, led the firm's deal team which also included Denver-based partner Ned Prusse and counsel Jonathan Schulman, Seattle-based partner Eric DeJong, and associates Christopher Wassman and Cassandra Wetzel.

Pacira BioSciences is a top provider of regenerative health treatments and non-opioid pain management committed to improving and advancing outcomes for healthcare practitioners and their patients.